Dogwood Therapeutics, Inc (NASDAQ:DWTX) Short Interest Up 78.9% in August

Dogwood Therapeutics, Inc (NASDAQ:DWTX – Get Free Report) was the recipient of a large increase in short interest in the month of August. As of August 31st, there was short interest totaling 89,398 shares, an increase of 78.9% from the August 15th total of 49,958 shares. Approximately 0.3% of the shares of the stock are sold short. Based on an average trading volume of 87,927 shares, the days-to-cover ratio is presently 1.0 days.

Dogwood Therapeutics Price Performance

DWTX stock traded up $0.11 during trading on Thursday, reaching $1.81. 7,826 shares of the company were exchanged, compared to its average volume of 76,889. The company has a market capitalization of $61.52 million, a price-to-earnings ratio of -0.20 and a beta of 1.81. The company has a 50-day moving average of $1.91 and a two-hundred day moving average of $1.92. Dogwood Therapeutics has a twelve month low of $1.28 and a twelve month high of $9.50.

Get Dogwood Therapeutics alerts:

Dogwood Therapeutics (NASDAQ:DWTX – Get Free Report) last released its quarterly earnings data on Thursday, August 13th. The company reported ($0.34) earnings per share for the quarter, missing the consensus estimate of ($0.14) by ($0.20). On average, analysts forecast that Dogwood Therapeutics will post -0.67 EPS for the current year.

Wall Street Analyst Weigh In

A number of brokerages recently commented on DWTX. Weiss Ratings restated a “sell (e+)” rating on shares of Dogwood Therapeutics in a research report on Friday, July 24th. HC Wainwright restated a “buy” rating on shares of Dogwood Therapeutics in a research report on Wednesday, September 2nd. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $12.00.

Check Out Our Latest Stock Report on Dogwood Therapeutics

About Dogwood Therapeutics

(Get Free Report)

Dogwood Therapeutics, Inc is a clinical-stage biotechnology company focused on developing treatments for diseases associated with neuroinflammation and viral-related immune dysfunction. The company’s research programs are aimed at conditions with limited therapeutic options, including fibromyalgia and symptoms associated with long COVID.

Dogwood’s lead investigational product, IMC-1, is a fixed-dose combination of the antiviral drug famciclovir and the anti-inflammatory medicine celecoxib.

Read More

• Five stocks we like better than Dogwood Therapeutics
• How Serious Is the Regulatory Threat Now Facing Tesla’s Cybercab?
• Can ServisFirst Keep Delivering?
• CoreWeave’s Vera Rubin Lead Comes Down to Speed, Power, and Scale
• Micron’s New 512GB Memory Module Deepens Its AI Infrastructure Advantage

Receive News & Ratings for Dogwood Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dogwood Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.